170 related articles for article (PubMed ID: 24671227)
1. Renal tumor size is an independent prognostic factor for overall survival in von Hippel-Lindau disease.
Kwon T; Jeong IG; Pak S; You D; Song C; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2014 Jul; 140(7):1171-7. PubMed ID: 24671227
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of renal cell carcinoma in Korean patients with von Hippel-Lindau disease compared to sporadic bilateral or multifocal renal cell carcinoma.
Kim WT; Ham WS; Ju HJ; Lee JS; Lee JS; Choi YD
J Korean Med Sci; 2009 Dec; 24(6):1145-9. PubMed ID: 19949673
[TBL] [Abstract][Full Text] [Related]
3. Survival and causes of death in patients with von Hippel-Lindau disease.
Binderup ML; Jensen AM; Budtz-Jørgensen E; Bisgaard ML
J Med Genet; 2017 Jan; 54(1):11-18. PubMed ID: 27539272
[TBL] [Abstract][Full Text] [Related]
4. A case of von Hippel-Lindau disease with bilateral pheochromocytoma, renal cell carcinoma, pelvic tumor, spinal hemangioblastoma and primary hyperparathyroidism.
Arao T; Okada Y; Tanikawa T; Inatomi H; Shuin T; Fujihira T; Yamashita H; Tanaka Y
Endocr J; 2002 Apr; 49(2):181-8. PubMed ID: 12081237
[TBL] [Abstract][Full Text] [Related]
5. Natural history of renal tumours in von Hippel-Lindau disease: a large retrospective study of Chinese patients.
Peng X; Chen J; Wang J; Peng S; Liu S; Ma K; Zhou J; Hong B; Zhou B; Zhang J; Cai L; Gong K
J Med Genet; 2019 Jun; 56(6):380-387. PubMed ID: 30745424
[TBL] [Abstract][Full Text] [Related]
6. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
[TBL] [Abstract][Full Text] [Related]
8. [Sarcomatoid renal cell carcinoma with von Hippel-Lindau disease: a case report].
Minagawa T; Nishizawa S; Kamigaito M; Nakayama T; Okaneya T
Nihon Hinyokika Gakkai Zasshi; 2007 Jul; 98(5):723-6. PubMed ID: 17682453
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and Economic Burden of von Hippel-Lindau Disease-Associated Renal Cell Carcinoma in the United States.
Jonasch E; Song Y; Freimark J; Berman R; Nguyen H; Signorovitch J; Sundaram M
Clin Genitourin Cancer; 2023 Apr; 21(2):238-247. PubMed ID: 36682891
[TBL] [Abstract][Full Text] [Related]
10. [A case of renal cell carcinoma associated with von Hippel-Lindau disease and the necessity for family genetic diagnosis].
Nanri M; Uda M; Iguchi Y; Gouya N; Toma H; Kihara T
Hinyokika Kiyo; 1999 Nov; 45(11):755-8. PubMed ID: 10637737
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous microwave ablation on management of hereditary renal cell carcinoma in Von Hippel-Lindau disease.
Chen J; Zheng L; Zhang W; Wang Z; Yu J; Liang P
Int J Hyperthermia; 2024; 41(1):2308079. PubMed ID: 38346873
[TBL] [Abstract][Full Text] [Related]
12. Nephron sparing surgery in von Hippel-Lindau associated renal cell carcinoma; clinicopathological long-term follow-up.
Jilg CA; Neumann HP; Gläsker S; Schäfer O; Leiber C; Ardelt PU; Schwardt M; Schultze-Seemann W
Fam Cancer; 2012 Sep; 11(3):387-94. PubMed ID: 22426863
[TBL] [Abstract][Full Text] [Related]
13. Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients.
Mans DA; Vermaat JS; Weijts BG; van Rooijen E; van Reeuwijk J; Boldt K; Daenen LG; van der Groep P; Rowland BD; Jans JJ; Roepman R; Voest EE; van Diest PJ; Verhaar MC; de Bruin A; Giles RH
J Pathol; 2013 Sep; 231(1):117-29. PubMed ID: 23744542
[TBL] [Abstract][Full Text] [Related]
14. Mutated Von Hippel-Lindau-renal cell carcinoma (RCC) promotes patients specific natural killer (NK) cytotoxicity.
Trotta AM; Santagata S; Zanotta S; D'Alterio C; Napolitano M; Rea G; Camerlingo R; Esposito F; Lamantia E; Anniciello A; Botti G; Longo N; Botti G; Pignata S; Perdonà S; Scala S
J Exp Clin Cancer Res; 2018 Dec; 37(1):297. PubMed ID: 30514329
[TBL] [Abstract][Full Text] [Related]
15. Growth kinetics in von Hippel-Lindau-associated renal cell carcinoma.
Jilg CA; Neumann HP; Gläsker S; Schäfer O; Ardelt PU; Schwardt M; Schultze-Seemann W
Urol Int; 2012; 88(1):71-8. PubMed ID: 22156657
[TBL] [Abstract][Full Text] [Related]
16. Natural history of Von Hippel-Lindau disease-associated and sporadic clear cell renal cell carcinoma: a comparative study.
Wang J; Zhang L; Qiu J; Li Z; Wu Y; Zhang C; Yao L; Gong K; Li X; Zhou L
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2631-2641. PubMed ID: 34709473
[TBL] [Abstract][Full Text] [Related]
17. Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation.
Gomy I; Molfetta GA; de Andrade Barreto E; Ferreira CA; Zanette DL; Casali-da-Rocha JC; Silva WA
Fam Cancer; 2010 Dec; 9(4):635-42. PubMed ID: 20567917
[TBL] [Abstract][Full Text] [Related]
18. Management of renal cell carcinoma in von Hippel-Lindau disease.
Hes FJ; Slootweg PJ; van Vroonhoven TJ; Hené RJ; Feldberg MA; Zewald RA; Ploos van Amstel JK; Höppener JW; Pearson PL; Lips CJ
Eur J Clin Invest; 1999 Jan; 29(1):68-75. PubMed ID: 10092992
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, morphology and biology of renal cell carcinoma in von Hippel-Lindau disease compared to sporadic renal cell carcinoma.
Neumann HP; Bender BU; Berger DP; Laubenberger J; Schultze-Seemann W; Wetterauer U; Ferstl FJ; Herbst EW; Schwarzkopf G; Hes FJ; Lips CJ; Lamiell JM; Masek O; Riegler P; Mueller B; Glavac D; Brauch H
J Urol; 1998 Oct; 160(4):1248-54. PubMed ID: 9751329
[TBL] [Abstract][Full Text] [Related]
20. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
